Notice of Appeal
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
NICE has received 1 appeal, that falls within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisations:
- Regeneron UK Ltd
The appeal panel will convene on Wednesday 3 September 2025 at 10:00am via Zoom to hear oral representations from the appellants.
Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.
Where possible, requests to attend should be made using the registration link that will be available on our website from Friday 20 June 2025. The registration period for this appeal will end at 4:00pm on Wednesday 27 August.
Further details relating to public attendance at this appeal are available on the same webpage as above.